The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 333:1417-1419 November 23, 1995 Number 21
NextNext

P-Glycoprotein — A Marker of Cancer-Cell Behavior

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Resistance to a broad array of cytotoxic drugs — multidrug resistance — is thought to be a major reason chemotherapy fails to cure most cancers. Multidrug resistance has been studied intensively since the human MDR1 gene was identified almost 10 years ago.1 Increased levels of the MDR1 product, called P-glycoprotein, are often associated in vitro with reduced intracellular concentrations of several anticancer drugs derived from plants, such as anthracyclines (e.g., doxorubicin), epipodophyllotoxins (e.g., etoposide), vinca alkaloids (e.g., vincristine), dactinomycin, and paclitaxel. When cells are grown in increasing concentrations of one of these cytotoxic drugs, populations of cells that overexpress the . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.